Chunxiao Sun None;
Hanako Ikeda Alcon Japan, Kyoto Drug Discovery & Development, Code F (Financial Support), Santen Pharmaceutical, Novartis Pharma, Senju Pharmaceutical, Alcon Pharma, Eisai, Code R (Recipient);
Tomoko Hasegawa None;
Shogo Numa Senju Pharmaceutical, Code R (Recipient);
Kenji Suda Alcon Japan, Code F (Financial Support), Santen Pharmaceutical, Senju Pharmaceutical, Kowa Pharmaceutical, Otsuka Pharmaceutical, Novartis Pharma, Code R (Recipient);
Masahiro Miyake Novartis Pharma, Code F (Financial Support), Bayer Yakuhin, Kowa Pharmaceutical, Alcon Japan, HOYA, Novartis Pharma, AMO Japan, Santen Pharmaceutical, Senju Pharmaceutical, Johnson & Johnson K.K., Code R (Recipient);
Takanori Kameda Alcon Japan, Code F (Financial Support), Alcon Japan, AMO Japan, Senju Pharmaceutical, Santen Pharmaceutical, Code R (Recipient);
Akitaka Tsujikawa Senju Pharmaceutical, Bayer Yakuhin, Novartis Pharma, HOYA, Ellex, MSD, Allegan Japan, Eisai, Daiich-Sankyo, Chugai Pharmaceutical, Code C (Consultant/Contractor), Canon, Findex, Santen Pharmaceutical, Kowa Pharmaceutical, Pfizer, AMO Japan, Senju Pharmaceutical, Wakamoto Pharmaceutical, Alcon Japan, Novartis Pharma, Otsuka Pharmaceutical, Bayer Yakuhin, Nitten Pharmaceutical, Code F (Financial Support), Bayer Yakuhin, Senju Pharmaceutical, Novartis Pharma, Santen Pharmaceutical, Alcon Pharma, AbbVie GK, AMO Japan, Kowa Pharmaceutical, Wakamoto Pharmaceutical, Code R (Recipient)